Cargando…

SARS-CoV-2 and the safety margins of cell-based biological medicinal products

With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modrof, Jens, Kerschbaum, Astrid, Farcet, Maria R., Niemeyer, Daniela, Corman, Victor M., Kreil, Thomas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456270/ https://www.ncbi.nlm.nih.gov/pubmed/32891497 http://dx.doi.org/10.1016/j.biologicals.2020.08.010

Ejemplares similares

Orthopox viruses and the safety margins of solvent‐detergent treated plasma‐derived medicinal products
por: Kindermann, Johanna, et al.
Publicado: (2022)

Measuring the effectiveness of gaseous virus disinfectants
por: Knotzer, Simone, et al.
Publicado: (2015)

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic
por: Schwaiger, Julia, et al.
Publicado: (2020)

West Nile Virus Infection in Plasma of Blood and Plasma Donors, United States
por: Planitzer, Christina B., et al.
Publicado: (2009)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
por: Karbiener, Michael, et al.
Publicado: (2022)

Longitudinal analysis of SARS‐CoV‐2 antibodies in 8000 U.S. first‐time convalescent plasma donations
por: Karbiener, Michael, et al.
Publicado: (2021)

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
por: Weidner, Lisa, et al.
Publicado: (2020)

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
por: Karbiener, Michael, et al.
Publicado: (2021)

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
por: Farcet, Maria R., et al.
Publicado: (2022)

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults
por: Wagner, Angelika, et al.
Publicado: (2021)

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice
por: Hohenadl, Christine, et al.
Publicado: (2014)

Sample Buffer Containing Guanidine-Hydrochloride Combines Biological Safety and RNA Preservation for SARS-CoV-2 Molecular Diagnostics
por: Weidner, Lisa, et al.
Publicado: (2022)

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic( )
por: Farcet, Maria R, et al.
Publicado: (2021)

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis
por: Lackner, Cornelia, et al.
Publicado: (2022)

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe( )
por: Farcet, Maria R, et al.
Publicado: (2022)

Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC
por: Farcet, Jean-Baptiste, et al.
Publicado: (2023)

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19
por: Zollner, Andreas, et al.
Publicado: (2021)

Synthesis of “Nereid,” a new phenol‐free detergent to replace Triton X‐100 in virus inactivation
por: Farcet, Jean‐Baptiste, et al.
Publicado: (2020)

SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
por: Garner-Spitzer, Erika, et al.
Publicado: (2022)

Authors’ response: SARS-CoV-2 detection by real-time RT-PCR
por: Corman, Victor M, et al.
Publicado: (2020)

Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
por: Leixner, Georg, et al.
Publicado: (2021)

Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic
por: Donoso Mantke, Oliver, et al.
Publicado: (2022)

Hosts and Sources of Endemic Human Coronaviruses
por: Corman, Victor M., et al.
Publicado: (2018)

Plasma procurement and plasma product safety in light of the COVID‐19 pandemic from the perspective of the plasma industry
por: Turecek, Peter L., et al.
Publicado: (2022)

Neutralizing Antibodies against SARS-CoV-2 and HLA Class I and II Polymorphism
por: Weidner, Lisa, et al.
Publicado: (2021)

International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020
por: Matheeussen, Veerle, et al.
Publicado: (2020)

Antibody‐enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin
por: Kapsch, Anna‐Maria, et al.
Publicado: (2020)

Use of marginal organs in kidney transplantation for marginal recipients: too close to the margins of safety?
por: Heuer, M, et al.
Publicado: (2010)

Conditional safety margins for less conservative peak local SAR assessment: A probabilistic approach
por: Meliadò, Ettore Flavio, et al.
Publicado: (2020)

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
por: Tonn, Torsten, et al.
Publicado: (2020)

Authors’ response: Plenty of coronaviruses but no SARS-CoV-2
por: Reusken, Chantal B, et al.
Publicado: (2020)

Production and secretion of functional SARS-CoV-2 spike protein in Chlamydomonas reinhardtii
por: Kiefer, Anna Maria, et al.
Publicado: (2022)

Antiviral activity of medicinal plant-derived products against SARS-CoV-2
por: de Oliveira, Jonatas Rafael, et al.
Publicado: (2022)

The Biology of Ocular Adnexal Marginal Zone Lymphomas
por: Johansson, Patricia, et al.
Publicado: (2022)

Biology of the SARS-CoV-2 Coronavirus
por: Mingaleeva, Rimma N., et al.
Publicado: (2023)

Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?
por: Toptan, Tuna, et al.
Publicado: (2021)

Correlation of SARS-CoV-2 RNA and nucleocapsid concentrations in samples used in INSTAND external quality assessment schemes
por: Valiente, Esmeralda, et al.
Publicado: (2023)

SARS‐CoV‐2 asymptomatic and symptomatic patients and risk for transfusion transmission
por: Corman, Victor M., et al.
Publicado: (2020)

Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases
por: Seidensticker, Max, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fmu3tn80krdo88dg07ejtcko3k